Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Born. Emmanuelle E; Lipskaia. Larissa L; Breau. Marielle M; Houssaini. Amal A; Beaulieu. Delphine D; Marcos. Elisabeth E; Pierre. Remi R; Do Cruzeiro. Marcio M; Lefevre. Marine M; Derumeaux. Genevieve G; Bulavin. Dmitry V DV; Delcroix. Marion M; Quarck. Rozenn R; Reen. Virinder V; Gil. Jesus J; Bernard. David D; Flaman. Jean-Michel JM; Adnot. Serge S; Abid. Shariq S
Key Findings
- Patients with pulmonary arterial hypertension have high levels of senescence markers (p16, p21) and DNA‑damage markers in lung tissue.
- In animal models, clearing senescent cells with FOXO4‑DRI or the drug ABT263 increased right‑ventricular pressure, heart enlargement, and vascular remodeling.
- Loss of senescent pulmonary endothelial cells (P‑ECs) after senolytic treatment correlated with worsening pulmonary hypertension symptoms.
Practical Outcomes
- For biohackers using FOXO4‑DRI as an anti‑aging senolytic, be aware that it may pose a risk to lung vascular health, especially if you have any underlying pulmonary or cardiovascular issues. Consider monitoring lung function and avoiding high‑dose or long‑term regimens until more safety data are available. Pairing senolytics with protective strategies for endothelial health might be necessary, but currently the evidence suggests caution rather than routine use.
Summary
Removing senescent cells with the FOXO4‑DRI peptide (a senolytic) can actually make lung blood pressure problems worse by killing important endothelial cells in the lungs. In mice and rats, using FOXO4‑DRI or other senolytics increased signs of pulmonary hypertension, especially when the animals were already stressed by low oxygen or other disease triggers.
Abstract
Senescent cells (SCs) are involved in proliferative disorders, but their role in pulmonary hypertension remains undefined. We investigated SCs in patients with pulmonary arterial hypertension and the role of SCs in animal pulmonary hypertension models. We investigated senescence (p16, p21) and DNA damage (γ-H2AX, 53BP1) markers in patients with pulmonary arterial hypertension and murine models. We monitored p16 activation by luminescence imaging in p16-luciferase (p16<sup>LUC/+</sup>) knock-in mice. SC clearance was obtained by a suicide gene (p16 promoter-driven killer gene construct in p16-ATTAC mice), senolytic drugs (ABT263 and cell-permeable FOXO4-p53 interfering peptide [FOXO4-DRI]), and p16 inactivation in p16<sup>LUC/LUC</sup> mice. We investigated pulmonary hypertension in mice exposed to normoxia, chronic hypoxia, or hypoxia+Sugen, mice overexpressing the serotonin transporter (SM22-5-HTT<sup>+</sup>), and rats given monocrotaline. Patients with pulmonary arterial hypertension compared with controls exhibited high lung p16, p21, and γ-H2AX protein levels, with abundant vascular cells costained for p16, γ-H2AX, and 53BP1. Hypoxia increased thoracic bioluminescence in p16<sup>LUC/+</sup> mice. In wild-type mice, hypoxia increased lung levels of senescence and DNA-damage markers, senescence-associated secretory phenotype components, and p16 staining of pulmonary endothelial cells (P-ECs, 30% of lung SCs in normoxia), and pulmonary artery smooth muscle cells. SC elimination by suicide gene or ABT263 increased the right ventricular systolic pressure and hypertrophy index, increased vessel remodeling (higher dividing proliferating cell nuclear antigen-stained vascular cell counts during both normoxia and hypoxia), and markedly decreased lung P-ECs. Pulmonary hemodynamic alterations and lung P-EC loss occurred in older p16<sup>LUC/LUC</sup> mice, wild-type mice exposed to Sugen or hypoxia+Sugen, and SM22-5-HTT<sup>+</sup> mice given either ABT263 or FOXO4-DRI, compared with relevant controls. The severity of monocrotaline-induced pulmonary hypertension in rats was decreased slightly by ABT263 for 1 week but was aggravated at 3 weeks, with loss of P-ECs. Elimination of senescent P-ECs by senolytic interventions may worsen pulmonary hemodynamics. These results invite consideration of the potential impact on pulmonary vessels of strategies aimed at controlling cell senescence in various contexts.
Study Information
pubmed
2022
2022-12-14T00:00:00.000Z
10.1161/circulationaha.122.058794